Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 6/20 | 0.59 |
| ▸ | CACNA1H | O95180 | 13/20 | 0.52 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18860180 | 0.94 | CACNA1I (0.61) | CACNA1ICACNA1HCACNA1GKCNH2CYP2D6 | |
| SCHEMBL18860178 | 0.94 | CACNA1I (0.61) | CACNA1ICACNA1HCACNA1GKCNH2CYP2D6 | |
| SCHEMBL18838359 | 0.94 | CACNA1I (0.61) | CACNA1ICACNA1HCACNA1GKCNH2CYP2D6 | |
| SCHEMBL18838314 | 0.89 | CACNA1I (0.60) | CACNA1ICACNA1HCACNA1GKCNH2CYP2D6 | |
| SCHEMBL18838318 | 0.89 | CACNA1I (0.60) | CACNA1ICACNA1HCACNA1GKCNH2CYP2D6 | |
| SCHEMBL29364770 | 0.89 | CACNA1I (0.60) | CACNA1ICACNA1HCACNA1GKCNH2CYP2D6 | |
| SCHEMBL18838406 | 0.89 | CACNA1I (0.60) | CACNA1ICACNA1HCACNA1GKCNH2CYP2D6 | |
| SCHEMBL18860331 | 0.87 | CACNA1I (0.45) | CACNA1ICACNA1HCACNA1GKCNH2 | |
| SCHEMBL18860337 | 0.86 | KCNH2 (0.59) | CACNA1ICACNA1HCACNA1GKCNH2CYP2D6 | |
| SCHEMBL18860274 | 0.86 | KMT2A (0.43) | CACNA1ICACNA1HCACNA1GCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | CACNA1I 1/4885CACNA1H 3/4885CACNA1G 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.